Please assess the completion status of the following clinical trial:

Trial Title: Etoricoxib in Acute Soft Tissue Rheumatism Affecting the Shoulder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Shoulder pain of acute onset of non-traumatic origin (less than 5 days).~* A history of painless unrestricted motion of the affected joint immediately before the acute attack.~* Acute one-sided shoulder pain caused by soft tissue rheumatism affecting the shoulder (bicipital tendinitis, rotator cuff tendinitis or subacromial bursitis) diagnosed by clinical signs and symptoms and confirmed by ultrasound evaluation.~* Patient-assessed pain on active movement exceeding 50 mm on a 100-mm visual analogue scale.~* Symptoms requiring therapy with NSAIDs.~Exclusion Criteria:~* Active or recurrent peptic (gastric or duodenal) ulcer.~* History of peptic ulcer or gastrointestinal bleeding.~* History of other bleeding disorders other than gastro-intestinal (e.g. cerebrovascular).~* Concomitant treatment with anti-coagulants (including heparin, ticlopidine, etc.), lithium, other NSAIDs (including aspirin doses \> 150 mg) or corticosteroids.~* Local injections of steroids in the affecting shoulder (within six months prior to the trial and during the trial).~* Presence of any form of crystal arthropathy (e.g. gout, pseudogout), destructive arthropathies (e.g. Charcot joints), infectious arthritis, chronic sepsis, osteonecrosis, rheumatoid inflammatory disease, previous~* shoulder surgery in the affected side, adhesive capsulitis in the affected side or cervical radiculopathy.~* Severe renal, cardiac or hepatic failure.~* Uncontrolled hypertension.~* Pregnancy or breast feeding.~* Confined to bed.~* Planned hospital stays or surgical procedures during the trial.~* Planned surgical intervention of the affected shoulder during the trial.~* Known alcohol or drug abuse.~* Inability to comply with the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Etoricoxib 60 mg per oz for 14 days
- 2 (Type: ACTIVE_COMPARATOR): Etoricoxib 90 mg per oz for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).